At its meeting on 4 July 2022 the Transparency Council adopted Position No. 62/2022 on the evaluation of the drug Keytruda (pembrolizumab) under the drug programme: “Treatment of patients with advanced colorectal cancer (ICD-10 C18-C20)”.
At its meeting on 4 July 2022 the Transparency Council adopted Position No. 62/2022 on the evaluation of the drug Keytruda (pembrolizumab) under the drug programme: “Treatment of patients with advanced colorectal cancer (ICD-10 C18-C20)”.